Drug Price Trends for MENOPUR

Average Pharmacy Cost for MENOPUR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MENOPUR 75 UNIT VIAL	55566-7501-02	243.30844	EACH	2025-04-04

Market Analysis and Price Projections for MENOPUR

Last updated: July 27, 2025

Introduction
MENOPUR, a human menopausal gonadotropin (hMG) derived from urine of postmenopausal women, primarily serves fertility clinics and reproductive endocrinologists for ovarian stimulation in assisted reproductive technology (ART). This comprehensive analysis assesses market dynamics, competitive landscape, regulatory considerations, and price projections to inform stakeholders’ strategic planning.

Market Overview
The global fertility drugs market, valued at approximately USD 4.5 billion in 2022, is expected to grow at a CAGR of over 7% through 2030 [1]. MENOPUR, as an established gonadotropin product, maintains a significant share within this segment, driven by increasing infertility prevalence and technological advances in ART.

Key Drivers and Trends

• Rising Infertility Rates: Globally, infertility affects an estimated 48 million couples, predominantly driven by factors such as age, lifestyle, and environmental influences [2]. This surge fuels demand for fertility treatments, especially gonadotropins like MENOPUR.
• Advances in ART: Innovations like in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) rely heavily on gonadotropin therapy, sustaining and expanding market needs.
• Regulatory Approvals and Reimbursement Policies: Stringent regulatory frameworks in different jurisdictions influence market entry and product adherence, impacting pricing strategies.
• Emerging Biosimilars: The entry of biosimilar versions of hMG could pressure prices but also expand access, especially in markets with cost-constrained healthcare systems.

Competitive Landscape
Major competitors include Ferring Pharmaceuticals (manufacturer of MENOPUR), Merck KGaA, Sa-sol, and biotech firms developing biosimilars. Ferring maintains a dominant position due to its early market entry and established manufacturing processes. However, the rise of biosimilars like Gemelli by BioPartners and other regional products introduces alternative options, possibly influencing MENOPUR pricing and market share.

Regulatory and Patent Considerations
Ferring holds key patents protecting MENOPUR’s formulations and manufacturing processes, which historically provided market exclusivity [3]. Patent expiry timelines differ across regions, opening opportunities for biosimilar entry and price competition in subsequent years.

Price Analysis
Current retail prices for MENOPUR vary significantly across regions, influenced by regulation, distribution channels, and reimbursement policies:

• United States: A typical 75 IU vial costs approximately USD 250–USD 350 wholesale, translating to patient prices of USD 300–USD 400 per vial after markup and insurance adjustments.
• European Markets: Prices range from €60 to €100 per 150 IU vial, with variations based on country-specific healthcare policies.
• Emerging Markets: Prices can be as low as USD 150 per vial, driven by lower manufacturing costs and competitive pricing strategies.

Availability of biosimilars and regional tendering policies exert downward pressure on prices, potentially reducing margins for Ferring and other suppliers.

Future Price Projections
Over the next five years, the price of MENOPUR is anticipated to experience moderate declines driven by biosimilar competition and pricing pressures, especially in mature markets:

• North America: Expect a decrease of 10–15% in wholesale prices within 3–5 years, assuming biosimilar adoption accelerates post-patent expiry around 2025.
• Europe: Prices may decline by 8–12%, especially in countries with aggressive tendering processes and cost-containment measures like the NHS in the UK.
• Emerging Markets: Prices are likely to stabilize or slightly decrease due to increased competition, but lower manufacturing costs may cushion the impact.

Meanwhile, Ferring’s strategy of maintaining premium pricing through brand strength and comprehensive clinical data suggests a gradual, controlled price erosion rather than abrupt cuts.

Market Entry and Expansion Opportunities
Emerging markets such as Southeast Asia, Latin America, and Africa represent upside potential due to historically lower penetration rates. Distribution partnerships and local manufacturing could enable Ferring to maintain competitive pricing while expanding access.

Regulatory Impact on Pricing
In jurisdictions where health authorities impose strict price caps or require biosimilar registration, MENOPUR’s price will align accordingly. For example, Germany’s reference pricing system strongly influences drug costs, potentially capping prices for originator products once biosimilars are introduced.

Conclusion
MENOPUR maintains a robust market position driven by established clinical efficacy and brand recognition. Price projections indicate a gradual decline driven by biosimilar competition, regional pricing strategies, and policy reforms. Stakeholders should prioritize early biosimilar adoption and regional market expansion to sustain profitability amid intensifying price competition.

---

Key Takeaways

• The global fertility drugs market continues to grow, with MENOPUR playing a critical role in ovarian stimulation therapies.
• Price erosion is expected over the coming years due to biosimilar entries and policy-driven price controls, especially in Europe and North America.
• Regional differences significantly influence pricing dynamics; emerging markets offer growth potential through affordable pricing and expanded access.
• Patents protection will support market exclusivity until approximately 2025; post-expiry, prices are likely to soften further.
• Strategic expansion into emerging markets and early biosimilar adoption are vital to maintaining margins.

---

FAQs

1. How will biosimilar products impact MENOPUR’s market share and pricing?
Biosimilars are expected to exert competitive pressure, potentially reducing prices by up to 20% within 2–3 years of market entry. This could lead to a decline in MENOPUR’s market share, prompting Ferring to focus on value-added services, clinical data, and regional partnerships to sustain its position.

2. What regional factors influence MENOPUR’s pricing strategies?
Regulatory policies such as reference pricing, reimbursement rates, and tendering practices are central. For example, Europe’s centralized procurement and cost-containment efforts often result in lower prices, while North American markets rely heavily on insurance reimbursements and negotiated discounts.

3. Are there upcoming patent expirations that could affect MENOPUR’s pricing?
Ferring’s key patents are expected to expire around 2025 in major markets, opening the door for biosimilar competitors and potential price reductions.

4. How might emerging markets affect the overall market outlook for MENOPUR?
Emerging markets hold considerable growth potential due to increasing infertility diagnoses and lower product penetration. Cost-conscious pricing and local manufacturing strategies will be vital to capture market share and offset revenue declines in mature regions.

5. What are the strategic considerations for stakeholders to optimize MENOPUR’s market position?
Investing in biosimilar development or licensing, expanding into underserved regions, and engaging with policymakers to influence pricing frameworks are critical strategies to sustain profitability amid an evolving competitive landscape.

---

Sources
[1] Market Research Future. Fertility Drugs Market Insights, 2022.
[2] WHO. Infertility Fact Sheet, 2021.
[3] Ferring Pharmaceuticals. Patent filings and regulatory documentation, 2022.